Cognitive-Bias Modification Therapy Helps Addicts Develop An 'Avoidance Bias'
Archives
All entries, chronologically...
The pharmaceutical industry is a “market for lemons,” a market in which the seller knows much more than the buyer about the product and can profit from selling products less effective and less safe than consumers are led to believe, according to an analysis by sociologist Donald Light that will be presented at the 105th Annual Meeting of the American Sociological Association. Light is a professor of comparative health policy at the University of Medicine and Dentistry of New Jersey.
BMED Report detailed the effectiveness of anti-depressant medication with only the most severely depressed in 2008 in “Anti-Depressant Medication & The Placebo Effect”. A new analysis of randomized trials indicates that compared with placebo, the magnitude of benefit of antidepressant medications varies with the severity of depressive symptoms, and may provide little benefit for patients [...]
In a huge development for the field of biofeedback, researchers* classified neurofeedback for childhood Attention Deficit Hyperactivity Disorder (ADHD) as “Level 5 – Efficacious and Specific” – the highest available efficacy rating established by ISNR and AABP. The investigators utilized a statistical technique called a meta-analysis to arrive at the results. Speaking from personal experience, neurofeedback clinicians have long known the powerful effects of EEG biofeedback for childhood attention and hyperactivity difficulties. Research trickled out over the years to provide support of these anecdotal clinical observations, but several recent well designed neurofeedback/ADHD studies allowed researchers to collect a minimum number of quality studies to conduct the current meta-analysis. For example, see Children With ADHD Realize Significant Benefits From Neurofeedback Training In a Randomized Clinical Trial reviewed on this website in February 2009.
I want to share 10 free online resources that can help clinicians improve their evidence-based decision making. Some of the resources are more common, while others may be new to you. Each resource listed also includes a short blurb directly from its website. As most clinicians know, evidence-based treatment planning is becoming more and more [...]
A recent meta-analysis* revealed that smokers who use a pharmacotherapy to aid in smoking cessation were twice as likely, on average, to maintain complete abstinence from cigarettes. Researchers analyzed 70 randomized controlled trials comprising 32,908 participants. Seven approved pharmacotherapies at 6 and 12 months of use were evaluated, including gum, inhaler, nasal spray, patch, and [...]
Autism Speaks and the Autism Clinical Trials Network report that a new low dose, melt-in-your-mouth version of Fluoxetine failed to reduce repetitive behaviors in children and adolescents diagnosed with Autism. Physicians’ clinical observations that Fluoxetine controlled these behaviors spurred this research. Fluoxetine is selective serotonin reuptake inhibitor (SSRI) that is commonly referred to as a “anti-depressant.” Researchers discovered that although Fluoxetine did reduce repetitive behaviors, the reductions were no greater than children given a sugar pill (placebo).
02/14/09 Update: AAPB removed the Evidenced-Based Biofeedback/Neurofeedback (2008 Edition) PDF because it is now offered only as regular book. Attached is the PDF of the 2004 edition of this book. Original Post: The Behavioral Medicine Report readers hopefully are becoming more familiar with biofeedback. Upcoming articles will cover other types of biofeedback treatments, not just [...]
